Residents and Fellows Research in Progress
Sunday, October 13, 2024
12:45 PM–02:15 PM
Abstract
Introduction: The Infectious Diseases Society of America recommends nitrofurantoin, sulfamethoxazole/trimethoprim, and fosfomycin for uncomplicated UTIs and fluoroquinolones or sulfamethoxazole/trimethoprim for pyelonephritis. While beta-lactams, including oral cephalosporins, are alternatives, their use is rising due to increasing resistance and adverse effects from other agents. In 2014, CLSI designated cefazolin as a surrogate marker for the susceptibility of seven oral cephalosporins, with a MIC breakpoint of <16 mcg/mL. However, the FDA has not supported this breakpoint due to limited data. Recent studies indicate that cefazolin may unreliably predict resistance to later-generation cephalosporins, with some resistant isolates still susceptible.
Research Question or Hypothesis: To determine if third generation cephalosporins are associated with treatment failure when used to treat urinary tract infections due to cefazolin-resistant urinary isolates.
Study Design: Retrospective, single-center study.
Methods: A retrospective chart review was conducted on adult patients discharged from the Emergency Department with cephalexin prescriptions for urinary tract infections or pyelonephritis. This review focused on cases where cephalexin was switched to a third-generation cephalosporin due to cefazolin resistance, covering the period from March 15, 2015, to March 15, 2024.
Results: To be presented at conference
Conclusion: To be presented at conference
Presenting Author
Ben Chiarolanza PharmDCHRISTUS Trinity Mother Frances Hospital
Authors
Mary Margaret Bliss PharmD
CHRISTUS Mother Frances Hospital
Corey Cicci PharmD, BCPS, BCEMP
CHRISTUS Trinity Mother Frances Health System
Craig Cocchio PharmD, BCPS, DABAT
Christus Trinity Mother Frances
Victoria Redshaw PharmD
CHRISTUS Trinity Mother Frances